Table 2.
Appearance of axillary nodes on post-treatment breast MRI.
| Axillary imaging findings | Neoadjuvant chemotherapy (n = 46) | Neoadjuvant endocrine therapy (n = 33) |
|---|---|---|
| BIRADS Features | ||
| Cortical thickness (≥3 mm) | 14 (30.4) | 12 (40.0) |
| Rounded morphology | 7 (15.2) | 7 (21.2) |
| Loss of fatty hilum | 7 (15.2) | 7 (21.2) |
| Asymmetrya | 13 (28.3) | 16 (48.5) |
| Any abnormal BIRADS feature | 16 (34.8) | 16 (48.5) |
| Number of abnormal nodes | ||
| None | 30 (65.2) | 17 (51.5) |
| Single | 8 (17.4) | 5 (15.2) |
| Multiple | 7 (15.2) | 9 (27.3) |
| Missing | 1 (2.2) | 2 (6.1) |
| Axillary level of involvement | ||
| None | 30 (65.2) | 17 (51.5) |
| Level I | 10 (21.7) | 11 (33.3) |
| Level I and II | 5 (10.9) | 0 (0.0) |
| Level I, II, and III | 0 (0.0) | 3 (9.1) |
| Missing | 1 (2.2) | 2 (6.1) |
aUnable to evaluate for 4 patients in chemotherapy cohort and 2 in endocrine therapy cohort.